Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Age is the key risk factor for diseases and disabilities of the elderly. Efforts to tackle age-
related diseases and increase healthspan have suggested targeting the ageing process …

Previous genome-wide association studies (GWASs) of stroke—the second leading cause of
death worldwide—were conducted predominantly in populations of European ancestry …

High-throughput proteomics platforms measuring thousands of proteins in plasma combined
with genomic and phenotypic information have the power to bridge the gap between the …

Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple
sclerosis have been developed and widely used. However, existing medications for multiple …

Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most
common type of neurodegenerative dementia. The prevalence of AD is expected to increase …

A diverse set of biological processes have been implicated in the pathophysiology of
Alzheimer's disease (AD) and related dementias. However, there is limited understanding of …

Proteomic studies for Alzheimer's disease (AD) are instrumental in identifying AD pathways
but often focus on single tissues and sporadic AD cases. Here, we present a proteomic study …

Developing a single-domain assay to identify individuals at high risk of future events is a
priority for multi-disease and mortality prevention. By training a neural network, we …

Alzheimer's disease (AD) is a neurodegenerative disease with unknown pathogenesis and
complex pathological manifestations. At present, a large number of studies on targeted …